Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LE did not state ¨that they were receiving some attractive scenarios out of the nearly 20 CDAs with others under review,.....¨.
The foowing quote by LE was in the 1/16/18 pr:“Datasets now in hand, reflecting three successfully completed Phase 2 studies across which multiple endpoints were met, have brought the Company to an important inflection point regarding Brilacidin. In coming weeks, we look forward to advancing these discussions with attractive partnership / licensing scenarios, ¨
As noted previously, ¨in coming weeks¨ has become months. What is his definition of coming weeks? 2,4,8,16,32,64,128,256,etc..?
I suppose the Clinical Study Report, along with compiling the Briefing Package, and meeting with the FDA will happen in the ¨coming weeks¨.
Thx lorema,
That could explain the B-OM ¨daly¨>
I don´t have to go beyond the first sentence which states;
¨The Company is currently focused on completing the Clinical Study Report for its Phase 2 clinical trial (see NCT02324335) evaluating Brilacidin’s ability to safely prevent and attenuate SOM in HNC patients receiving chemoradiation and compiling a Briefing Package for discussion with the FDA.¨
My only question is: Is a Clinical Study Report typical? Not according to wiki, were wiki states ¨Results of trials are usually reported in a briefer academic journal paper, but methodological flaws are often glossed over in the briefer paper.¨
https://en.wikipedia.org/wiki/Clinical_study_report
I suspect the fda has their own definition.
lousy engineer(spare us, you have the same initials as Leo Erlich(coincidence I hope),
Lets break down your post.
1. ¨Why bother breaking down TIAB's post?¨
It´s what one should do with each post(consideration). One should try and decipher any and all arguments, and statements, and reckon an opinion. IMO, clearly, you think otherwise.
2. ¨What's so special about it?¨
Nothing, to you. Does not mean his/her post did not trigger questions elsewhere.
58nout,
Lets break down TIABs post.
1.¨Good news must be just around the corner, check that¨
I would have substituted the word must with could. BS sniff test-nuetral(he took a check swing).
2.TIAB continues from 1 above:¨we have fallen by almost half instead of rising.¨
BS sniff test. TIAB statement is true.
3.TIAB then asks¨What could that(1&2 above) mean?(¨fallen by almost half instead of rising¨). BS sniff test- neutral, a fair question, to which only a few know the answer to.
4.TIAB questions his/her own question(3 above) and wonders his/her own question as noted in:¨ other than imminent P2b failure announcement? ¨
BS sniff test, PU. I was taught you should not answer a question with another question w/o justifying your question with proof.
TIAB, not bashing you(I believe you hope, as many of us do, that this investment shall pan out), just responding.
83 days since the 12/21/17 pr stating final patient inp2b trial.
58 days(eight weeks and two days) since the 1/16/18 pr which included the following LE quote:
“Datasets now in hand, reflecting three successfully completed Phase 2 studies across which multiple endpoints were met, have brought the Company to an important inflection point regarding Brilacidin. In coming weeks, we look forward to advancing these discussions with attractive partnership / licensing scenarios, towards determining the best path forward for the Company and its loyal shareholders.”
News has to close. If not LE should clarify coming ¨weeks¨.
BooDog,
My main question has not changed. Re-read my initial post, and substitute B for P(I put P, but if you read the rest of the post, I clearly was referencing B-OM). As a moderator of this board, you clearly should be able to make sense of my error(referring to B as P, missed by that much, as Maxwell Smart would say). I trust LE and AB have spent much time under the cone of silence the past few months, and trust we shall beat chaos.
JTORENCE,
I agree. My bad. The statements I made are factual to B-OM, not P. Sorry. My father always advised to measure twice and cut once, can often lead to additional work if you don(correcting posts in this case).
Please accept my apology.
BooDog,
I? trying to sort the following:
IPIX primary outcome measures as defined in clinicaltrials.gov:
A.
1. Incidence of severe oral mucositis (WHO Grade ≥3) [ Time Frame: 7 weeks ]
Incidence of severe oral mucositis, defined as grade 3 or 4 on the WHO Oral Mucositis score, experienced during radiation therapy by patients with head and neck cancer receiving a cumulative radiation dose of at least 55 Gy. The WHO Score will be assessed by trained site personnel twice-weekly.
2. Incidence of Treatment-Emergent Adverse Events [ Time Frame: 11 weeks ]
Reporting of Adverse Events and severity of adverse events
B.
1. From the 2/7/18 10q, pg 23, third paragraph down:
Given that Brilacidin-OM successfully prevented SOM from occurring, as well as delayed its onset, in a substantial number of patients, data comparisons aimed at assessing potential reduction in the duration of SOM were constrained by the fewer number of Brilacidin-OM treated patients that could be included in such analysis. While Brilacidin-OM appeared to decrease the initial duration of SOM (time from the initial WHO Grade ≥ 3 to the first WHO Grade ≤ 2 OM assessment), detailed interpretation of this and other duration data comparisons were limited.
Based on the last eleven words of the last setence (¨detailed interpretation of this and other duration data comparisons were limited.¨), tells me there is more data analysis to come, hopefully.
How can something be conclusive if the interpretations are limited?
Thx George, my bad. I meant to refer to B-OM, not P.
Response, Take 2:
Regarding B-OM, its been 218 days since enrollment was completed pr(8/7/17) and 82 days since the last patient visit pr(12/21/17).
Galera announced enrollment completion for their ph2 OM drug candidate GC4419 on 6/15/17. They announced results 187 days later on 12/18/17, They then announced fda BTD 73 days later on 2/28/18.
Galera had nearly 4 times as many sites(61 vs our 16), 22% more total outcome measures(22 vs. our 18), nearly 4 times patient enrollment(233 vs our 61).
Appreciate the fact check.
kfc
BooDog,
I do not suspect them to be hard at work, I expect them to be hard at work(the natural satisfaction gained through work). If they are not hard at work(conniving does not count as work), we have problems.
Regarding P, its been 218 days since enrollment was completed pr(8/7/17) and 82 days since the last patient visit pr(12/21/17).
Galera announced enrollment completion for their ph2b psoriasis drug candidate GC4419 on 6/15/17. They announced results 187 days later on 12/18/17, They then announced fda BTD 73 days later on 2/28/18.
Galera had nearly 4 times as many sites(61 vs our 16), 22% more total outcome measures(22 vs. our 18), nearly 4 times patient enrollment(233 vs our 61).
Based on my simple assessment of numbers and figures noted above, I expect an announcement soon, real soon.
I agree.
Just because KM is now in FL while collecting half his former pay, does not concern me.
I believe LE and AB will soon make an announcement.
Sox040713,
¨As you can see, ~65K shares per day created a tremendous selling pressure for a stock that averaged ~200K. If you have a dedicated seller with 65K shares (supply) but don't have an equally dedicated buyer (demand), the SP is more likely to decline.¨
I agree.
I analyzed it a bit differently, that is, how much money did they raise per calendar day.
7/1/17 to 9/5/17 they received ~ $2.1M. $2100000/67 days= $31343/cal.day.
9/6/17 to 12/31/17 they received ~ $4.4M. $4400000/117 calendar days= $37,606/cal. day.
1/1/18 to 2/7/18 they received ~ $.6M. $600,000/38 calendar days= $15,789/cal. day.
Could easily have figured the working days, but some expenses are monthly(ie rent, utilities(if not covered by landlord), vehicles, etc).
Anyhow, the last dip in the well clearly shows a reduction in expenses. I´d like to know where that $15k/cal day goes.I believe rent is 18k/mo(660/day), LE salary of 8k/mo(266/cal. day).
I recognize there outside venders, contrtactors etc.
Should here something soon.
Suvorov,
Concise response. Your opening sentence is spot on(¨One can examine a financial structure of a company as well as examine the chart history and combine both and others into a predictive software program..).
I will say I am not in the same camp as you(I believe you think ipix will fail), however, as stated above, you presented a well thought out argument(response).
Stocks can be like weather, and often times the weathermans predictions do not hold true.
At least in New England.
Georgejjl,
Please stop your repeated posting of Nerby's post. The post was made, but all statements within it are currently unverifiable(much as your statements, more than a year ago, that the share price would triple by the end of February, 2017).
Enough((and I´m long(but also frustrated with this investment)). Have begun inquiries.
Tired of the arguments:
Hope most enjoy the MUSIC.
Septmike09,
Pardon me for not reading the total thread, but are you suggesting the current sp is a harbinger for a rs?
If so, why buy at these current sp's?
Thx
I added 50k.
Good point. What is the name of their General Counsel in Beverly?
George,
You've reposted "Nerby's" post#198526 numerous times since it was first posted on 9/29/17. The poster(Nerby) has vanished, the sp was 33% higher(testing new lows then), and LE does not return calls.
Who here has attempted to call the listed phone # and got anyone? If yes, who answered, and on what date?
Maybe the link below explains things better than Nerby's post# 198526 does.
George,
You continue to "plow" stuff upon other posters, seldom questioning mngt, and quoting yourself.
Believe me, I hope your declarations are proven true but must say I'm entertaining all alternative options of inquiry.
George,
You advise all to"Follow the FACTS".
The simplest of facts is, the most important facts (trial results) have yet to be unblinded and conveyed.
You seem to be an expert in not only biotech, but the inner workings of WS and finance(to quote you"the sp will triple by the end of Feb 2017"). To qoute you again,"The MMs start the sell momentum and profit off the downward pressure on the share price. " Makes me wonder, are you one of the MM's? You seem quite content after years of sp loss.
My hope is declining, but still more than hopeful(not by much). I'm beginning to wonder if LE's prior occupation was an undertaker.
"I think your chart is more a reflection of your efforts than it is on some dishonest person sharing what they know about trial results. "
Interesting sentence. Are his/her efforts honest, or dishonest, and are they(those efforts) the primary influence regarding sp performance? In regards to the latter part of your sentence("...some dishonest person sharing what they know about trial results."), put the way in which you phrased it, I hope it's the leading part of your sentence as sp should correct. If it's the latter, there will be a lot of money lost, time wasted, and a wee bit of additional tax burden to service a couple more jail cells.
Maybe Michael Sullivan ain't as smart as I thought.)
Williamsc,
I would have also amended the last two words from your 1st paragraph from "loyal shareholders", to "storm tossed shareholders":).
Georgejjl,
I agree with your statement(in response to RG) that "News could be released any day!!! The anticipation is increasing each and every day!!! ", mainly based on the last two sentences of paragraph 4 of their 1/16/18 pr: “Datasets now in hand, reflecting three successfully completed Phase 2 studies across which multiple endpoints were met, have brought the Company to an important inflection point regarding Brilacidin. In coming weeks, we look forward to advancing these discussions with attractive partnership / licensing scenarios, towards determining the best path forward for the Company and its loyal shareholders.”
This Monday (2/6/18) will complete week seven since that 1/16/18 pr. Perhaps ""coming weeks" should have re-phrased as "coming weeks, month, or possibly more", as come 3/16/18 the time frame becomes months. I believe their studies have generated more interest since SF(see 1/16/18 pr) as reflected in their 1/29/pr where they note, in part " The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review."
http://www.ipharminc.com/press-release/2018/1/16/innovation-pharmaceuticals-presents-at-2018-biotech-conference-oral-mucositis-drug-candidate-garners-exceptional-interest-after-successful-phase-2-trial
http://www.ipharminc.com/press-release/2018/1/29/innovation-pharmaceuticals-brilacidin-franchise-anchored-in-three-clinical-indications-oral-mucositis-inflammatory-bowel-disease-and-serious-skin-infections-expands-into-dermatologic-diseases
LGD,
May we all be smiling soon.
Is that to suggest silence is golden?
Defending neither your argument nor Suvorov's. But why does the sp continually decline if "Right now all who bought are in a holding pattern somewhere over the US. P data or B partnership on the plate."? The sp has declined nearly 22.5% since its closing price on 12/1/17, and that's with encouraging pr's since then. I'm long, but it is time for LE or AB to step up. They shall lose the loyal shareholders LE fondly references if not.
Bunny,
Learn to smile once and a while.
Growing pains.
Exactly. As someone once stated, "The stock price is becoming ugly fugly to say the least.".
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=123871636
I disagree but appreciate the humor. That's funny. Thanks for the chuckle.
LGD,
Oops, sorry. Forwarded wrong link(you don't steal my heart away).
LilyGDog,
Agree. I don't know you, nor, do you know me.
TIAB,
It's barely started. From the sound of things, the coast will be quite lively during the next 24 hours.
I have no worries. The Captain of this ship will soon land us on Fantasy Island.
Those that didn't store a pail before they pulled up anchor may be in trouble. Nothing like riding a Nor'easter in a wooden rowboat when the storm strikes. Oar, put another way....
LilyGDog,
I'm with you. I have almost twice as many shares as HereToday(bought years ago @ average price of $3.52). I have no concerns about sp as the science rules.
Thanks Billy:)
Georgejjl,
Appreciate your post but, how do you know this? Should your quote " A short list of companies interested in Prurisol, Brilacidin and Kevetrin" be modified with the words "that may be" inserted between the words companies and interested( the bolded words in this response)?
Where did you get this information(or is it disinformation?)
Your proclamations ring hollow(but I now suspect your wallet has bulged within the past year as you advised, back then, that the sp would triple by the end of Feb. 2017).
Competition is healthy, and I believe we're in the mix still. Georgejjl ramblings, are just that:
https://www.slideshare.net/Vijaymishrapsmarket/oral-mucositis-therapeutics-pipeline-analysis-2017-by-ps-market-research
septmike09,
You state:
"Nerby didn't go underground. The post is more than likely legit. You should do a little more DD."
No word from Nerby since post#198528 which was in to your response(198527) which was in response to Nerby's post 198526(which George often sights as to P's prowess). Nerby's last two posts were made within 26 minutes of each other, the last being on 9/30/17 just after midnight.
So perhaps you are correct(and I hope you are) that he is not "underground as taas phrased it, but Nerby has not posted in 5 months.